

- venous immunoglobulin. *Science* 1998; 282(5388): 490–493.
38. Firoz BF, Henning JS, Zarzabal LA, Pollock BH. Toxic epidermal necrolysis: five years of treatment experience from a burn unit. *J Am Acad Dermatol* 2012; 67(4): 630–635.
 39. Stella M, Cassano P, Bollero D, Clemente A, Giorio G. Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience. *Dermatology* 2001; 203(1): 45–49.
 40. Tristani-Firouzi P, Petersen MJ, Saffie JR, Morris SE, Zone JJ. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. *J Am Acad Dermatol* 2002; 47(4): 548–552.
 41. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. *Arch Dermatol* 2003; 139(1): 33–36.
 42. Campione E, Marulli GC, Carrozzo AM, Chimenti MS, Costanzo A, Bianchi L. High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis. *Acta DermVenereol* 2003; 83(6): 430–432.
 43. Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using Scorten: The University of Miami Experience. *Arch Dermatol* 2003; 139(1): 39–43.
 44. Prins C, Kerdel FA, Padilla RS, Hunziker T, Chimenti S, Viard I, Mauri DN, Flynn K, Trent J, Margolis DJ, Saurat JH, French LE. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. *Arch Dermatol* 2003; 139(1): 26–32.
 45. Al-Mutairi N, Arun J, Osama NE, Amr Z, Mazen AS, Ibtisam el-A, Nazeha el-B. Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis. *Int J Dermatol* 2004; 43(11): 847–851.
 46. Brown KM, Silver GM, Halzer M, Walaszek P, Sandroni A, Gamelli RL. Toxic epidermal necrolysis: does immunoglobulin make a difference? *J Burn Care Rehabil* 2004; 25(1): 81–88.
 47. Shortt R, Gomez M, Mittman N, Cartotto R. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. *J Burn Care Rehabil* 2004; 25(3): 246–255.
 48. Kim KJ, Lee DP, Suh HS, Lee MW, Choi JH, Moon KC, Koh JK. Toxic epidermal necrolysis: analysis of clinical course and SCORTEN-based comparison of mortality rate and treatment modalities in Korean patients. *Acta Derm Venereol* 2005; 85(6): 497–502.
 49. Lissia M, Figus A, Rubino C. Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report. *Br J Plast Surg* 2005; 58(4): 504–510.
 50. Mangla K, Rastogi S, Goyal P, Solanki RB, Rawal RC. Efficacy of low dose intravenous immunoglobulins in children with toxic epidermal necrolysis: an open uncontrolled study. *Indian J Dermatol Venereol Leprol* 2005; 71(6): 398–400.
 51. Tan AW, Thong BY, Yip LW, Chng HH, Ng SK. High-dose intravenous immunoglobulins in the treatment of toxic epidermal necrolysis: an Asian series. *J Dermatol* 2005; 32(1): 1–6.
 52. Yeung CK, Lam LK, Chan HH. The timing of intravenous immunoglobulin therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis. *Clin Exp Dermatol* 2005; 30(5): 600–602.
 53. Yip LW, Thong BY, Tan AW, Khin LW, Chng HH, Heng WJ. High-dose intravenous immunoglobulin in the treatment of toxic epidermal necrolysis: a study of ocular benefits. *Eye (Lond)* 2005; 19(8): 846–853.
 54. Imahara SD, Holmes JH 4th, Heimbach DM, Engrav LE, Honari S, Klein MB, Gibran NS. SCORTEN overestimates mortality in the setting of a standardized treatment protocol. *J Burn Care Res* 2006; 27(3): 270–275.
 55. Paquet P, Kaveri S, Jacob E, Pirson J, Quatresooz P, Piérard GE. Skin immunoglobulin deposition following intravenous immunoglobulin therapy in toxic epidermal necrolysis. *Exp Dermatol* 2006; 15(5): 381–386.
 56. Gravante G, Delogo D, Marianetti M, Trombetta M, Espósito G, Montone A. Toxic epidermal necrolysis and Steven Johnson syndrome: 11-years experience and outcome. *Eur Rev Med Pharmacol Sci* 2007; 11(2): 119–127.
 57. Stella M, Clemente A, Bollero D, Rizzo D, Dalmaso P. Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis. *Burns* 2007; 33(4): 452–459.
 58. Cartotto R, Mayich M, Nickerson D, Gomez M. SCORTEN accurately predicts mortality among toxic epidermal necrolysis patients treated in a burn center. *J Burn Care Res* 2008; 29(1): 141–146.
 59. Dorafshar AH, Dickie SR, Cohn AB, Aycock JK, O'Connor A, Tung A, Gottlieb LJ. Antishear therapy for toxic epidermal necrolysis: an alternative treatment approach. *Plast Reconstr Surg* 2008; 122(1): 154–160.
 60. Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. *J Am Acad Dermatol* 2008; 58(1): 33–40.
 61. Rajaratnam R, Mann C, Balasubramaniam P, Marsden JR, Taibjee SM, Shah F, Lim R, Papini R, Moiemien N, Lewis H. Toxic epidermal necrolysis: retrospective analysis of 21 consecutive cases managed at a tertiary centre. *Clin Exp Dermatol* 2010; 35(8): 853–862.
 62. Atzori L, Pinna AL, Mantovani L, Ferrelli C, Pau M, Mulargia M, Aste N. Cutaneous adverse drug reactions to allopurinol: 10 year observational survey of the dermatology department—Cagliari University (Italy). *J Eur Acad Dermatol Venereol* 2012; 26(11): 1424–1430.
 63. Zhu QY, Ma L, Luo XQ, Huang HY. Toxic epidermal necrolysis: performance of SCORTEN and the score-based comparison of the efficacy of corticosteroid therapy and intravenous immunoglobulin combined therapy in China. *J Burn Care Res* 2012; 33(6): e295–e308.
 64. Jagadeesan S, Sobhanakumari K, Sadanandan SM, Ravindran S, Divakaran MV, Skaria L, Kurien G. Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: a prospective comparative open-labelled study of 36 cases. *Indian J Dermatol Venereol Leprol* 2013; 79(4): 506–511.
 65. Lee HY, Lim YL, Thirumoorthy T, Pang SM. The role of intravenous immunoglobulin in toxic epidermal necrolysis: a retrospective analysis of 64 patients managed in a specialized centre. *Br J Dermatol* 2013; 169(6): 1304–1309.
 66. Aihara M, Kano Y, Fujita H, Kambara T, Matsukura S, Katayama I, Azukizawa H, Miyachi Y, Endo Y, Asada H, Miyagawa F, Morita E, Kaneko S, Abe R, Ochiai T, Sueki H, Watanabe H, Nagao K, Aoyama Y, Sayama K, Hashimoto K, Shiohara T. Efficacy of additional i.v. immunoglobulin to steroid therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis. *J Dermatol* 2015; 42(8): 768–777.
 67. Lalosevic J, Nikolic M, Gajic-Veljic M, Skiljevic D, Medenica L. Stevens-Johnson syndrome and toxic epidermal necrolysis: a 20-year single-center experience. *Int J Dermatol* 2015; 54(8): 978–984.
 68. Yang L, Shou YH, Li F, Zhu XH, Yang YS, Xu JH. Retrospective study of 213 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis from China. *Burns* 2019; S0305-4179(19)30459-0.
 69. Krajewski A, Mazurek MJ, Mlynska-Krajewska E, Piorun K, Knakiewicz M, Markowska M. Toxic epidermal necrolysis therapy with TPE and IVIG-10 years of experience of the Burns Treatment Center. *J Burn Care Res* 2019; 40(5): 652–657.
 70. Zimmermann S, Sekula P, Venhoff M, Motschall E, Knaus J, Schumacher M, Mockenhaupt M. Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. *JAMA Dermatol* 2017; 153(6): 514–522.
 71. Borilova Linhartova P, Gachova D, Lipovy B. Responsiveness to i.v. immunoglobulin therapy in patients with toxic epidermal necrolysis: A novel pharmaco-immunogenetic concept. *J Dermatol* 2020. doi: 10.1111/1346-8138.15583.